Patents Examined by Satyendra Singh
-
Patent number: 8323339Abstract: A method for manufacturing a delivery system that includes a bone growth promoting material encapsulated within a water-absorbing, water-gelatinizable covering used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit within a bleeding wound (e.g., one that is formed in the gingiva when a tooth is extracted). The covering may be formed of a gelatinizable-gauze (e.g., oxidized cellulose) that forms a gel-like material when moistened with water. The delivery system may be stored in a moisture resistant package prior to use.Type: GrantFiled: September 2, 2008Date of Patent: December 4, 2012Assignee: Ultradent Products, Inc.Inventor: Dan E. Fischer
-
Patent number: 8318212Abstract: Disclosed is a method for regenerating articular cartilage in an animal comprising administering a therapeutically effective amount of a non-demineralized particulate articular cartilage having a distribution of particle sizes within the range of from about 60 microns to about 500 microns.Type: GrantFiled: November 5, 2010Date of Patent: November 27, 2012Assignee: University of MiamiInventor: Theodore I. Malinin
-
Patent number: 8309346Abstract: A non-invasive measurement of biological tissue reveals information about the function of that tissue. Polarized light is directed onto the tissue, stimulating the emission of fluorescence, due to one or more endogenous fluorophors in the tissue. Fluorescence anisotropy is then calculated. Such measurements of fluorescence anisotropy are then used to assess the functional status of the tissue, and to identify the existence and severity of disease states. Such assessment can be made by comparing a fluorescence anisotropy profile with a known profile of a control.Type: GrantFiled: October 10, 2007Date of Patent: November 13, 2012Inventor: Ralph Zuckerman
-
Patent number: 8293488Abstract: A method for discovering neurogenic drugs is revealed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and/or the number of neurons.Type: GrantFiled: September 10, 2007Date of Patent: October 23, 2012Assignee: Neuralstem, Inc.Inventors: Judith Kelleher-Andersson, Karl K. Johe
-
Patent number: 8277828Abstract: A delivery system that includes a bone growth promoting material encapsulated within a water absorptive gelatinizable covering is used to promote bone growth in order to repair a bone defect and/or strengthen a weakened bone region. The delivery system may be shaped and sized in order to fit within a bleeding wound (e.g. one that is formed in the gingiva when a tooth is extracted). The covering may be formed of a gelatinizable gauze that forms a gel-like material when moistened with water. The delivery system is contained within a moisture resistant package prior to use. Alternatively, the delivery system comprises a bone growth promoting material and thickening agent contained within a syringe that, upon adding water, form a viscous gel or stiff putty. A polymerizable resin may be placed over the bone growth composition after placement on a bone to form a protective barrier layer.Type: GrantFiled: October 13, 2006Date of Patent: October 2, 2012Assignee: Ultradent Products, Inc.Inventor: Dan E. Fischer
-
Patent number: 8257932Abstract: Disclosed herein are methods and materials by which nanostructures such as carbon nanotubes, nanorods, etc. are bound to lectins and/or polysaccharides and prepared for administration to cells. Also disclosed are complexes comprising glycosylated nanostructures, which bind selectively to cells expressing glycosylated surface molecules recognized by the lectin. Exemplified is a complex comprising a carbon nanotube functionalized with a lipid-like alkane, linked to a polymer bearing repeated ?-N-acetylgalactosamine sugar groups. This complex is shown to selectively adhere to the surface of living cells, without toxicity. In the exemplified embodiment, adherence is mediated by a multivalent lectin, which binds both to the cells and the ?-N-acetylgalactosamine groups on the nanostructure.Type: GrantFiled: February 20, 2008Date of Patent: September 4, 2012Assignee: The Regents of the University of CaliforniaInventors: Xing Chen, Carolyn R. Bertozzi, Alexander K. Zettl
-
Patent number: 8252591Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: May 6, 2005Date of Patent: August 28, 2012Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's HospitalInventors: Tan A. Ince, Robert A. Weinberg
-
Patent number: 8252524Abstract: A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.Type: GrantFiled: August 26, 2009Date of Patent: August 28, 2012Assignees: Kowa Company, Ltd., Nissan Chemical Industries, Ltd.Inventors: Takahide Kohro, Yoshikazu Shibasaki, Takao Hamakubo, Tatsuhiko Kodama
-
Patent number: 8236517Abstract: A BUN (blood urea nitrogen) sensor containing immobilized carbonic anhydrase and immobilized urease for the in vitro detection of urea nitrogen in blood and biological samples with improved performance and precision characteristics.Type: GrantFiled: February 25, 2009Date of Patent: August 7, 2012Assignee: Abbott Point of Care Inc.Inventors: G. Bruce Collier, Eric Brouwer, Anjulia Wong
-
Patent number: 8216776Abstract: An aqueous solution of electrolytes, a sugar osmotic agent and a physiologically safe salt of a reductive sulfur oxy-acid. Alternatively, the dialysate comprises an aqueous solution of electrolytes, a salt of a reductive sulfur oxy-acid, and osmotic agents which contain an oncotic agent other than a sugar osmotic agent.Type: GrantFiled: May 11, 2010Date of Patent: July 10, 2012Assignee: Japan Science and Technology CorporationInventors: Asahi Sakai, Masaaki Nakayama
-
Patent number: 8211663Abstract: A biological indicator and method of making same. The biological indicator includes a carrier having a recess formed therein in order to restrict movement of an inoculum deposited onto the carrier. The inoculum includes microorganisms (e.g., bacterial spores) suspended in a suspension medium. The microorganisms are prepared by removing extraneous material and subjecting the microorganisms to sonication to break up agglomerations. The suspension medium includes a wetting agent to reduce surface tension, thereby facilitating flow of the suspension medium to prevent stacking of microorganisms on the surface of the carrier, and to allow the inoculum to more evenly “plate out” on carrier surfaces. The carrier, with inoculum deposited thereon, is enclosed in an envelope made of a material permeable to a vaporous deactivating agent (e.g., vaporized hydrogen peroxide, ozone, chlorine dioxide, ethylene oxide, etc.), thereby facilitating exposure to the vaporous deactivating agent.Type: GrantFiled: August 12, 2009Date of Patent: July 3, 2012Assignee: American Sterilizer CompanyInventors: Anthony W. Dallmier, Christopher W. Fisher, Timothy J. Millett
-
Patent number: 8182807Abstract: The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent.Type: GrantFiled: February 19, 2008Date of Patent: May 22, 2012Assignee: Board of Regents of the University of Nebraska by and on Behalf of the University of Nebraska Medical CenterInventors: Vinod D. Labhasetwar, Maram K. Reddy
-
Patent number: 8142993Abstract: Methods of producing neutrophil-depleted platelet-rich plasma by passing a blood, platelet or platelet-rich plasma fraction through a narrow, twisted and/or charged environment to remove neutrophils and produce neutrophil-depleted platelet-rich plasma is described. The neutrophil-depleted platelet-rich plasma may be depleted in neutrophils by 75% or more and includes at least 0.5×106 platelets per ml. The pH of the neutrophil-depleted platelet-rich plasma may be adjusted to 7.3-7.5.Type: GrantFiled: December 16, 2011Date of Patent: March 27, 2012Inventor: Allan Mishra
-
Patent number: 8137702Abstract: A conformable tissue implant is provided for use in repairing or augmenting a tissue defect or injury site. The tissue implant contains a tissue carrier matrix comprising a plurality of biocompatible, bioresorbable granules and at least one tissue fragment in association with the granules. The tissue fragment contains one or more viable cells that can migrate from the tissue and populate the tissue carrier matrix. Also provided is a method for injectably delivering the tissue implant.Type: GrantFiled: December 29, 2010Date of Patent: March 20, 2012Assignee: DePuy Mitek, Inc.Inventors: Francois Binette, Joseph J. Hammer, Krish Mukhopadhyay, Joel Rosenblatt
-
Patent number: 8129105Abstract: A non-invasive measurement of biological tissue reveals information about the function of that tissue. Polarized light is directed onto the tissue, stimulating the emission of fluorescence, due to one or more endogenous fluorophors in the tissue. Fluorescence anisotropy is then calculated. Such measurements of fluorescence anisotropy are then used to assess the functional status of the tissue, and to identify the existence and severity of disease states. Such assessment can be made by comparing a fluorescence anisotropy profile with a known profile of a control.Type: GrantFiled: January 19, 2007Date of Patent: March 6, 2012Assignee: Ralph ZuckermanInventor: Ralph Zuckerman
-
Patent number: 8128952Abstract: Disclosed are systems and methods that can be utilized to define and control the delivery rate of a biological agent from a carrier matrix such as a biocompatible hydrogel. The carrier matrices of the present invention can include ligands incorporated within the matrix at a predetermined concentration level (CLT). In addition, the ligands within the matrix can display a particular, predetermined affinity for the biologically active agents to be delivered by the system. In particular, the affinity between the ligand and the biologically active agent can have a known predetermined dissociation constant (KD). When utilizing the system, the agent can be incorporated within the matrix due to association of the agent with the ligand. In addition, the agent can be protected from side reactions due to the association of the agent with the ligand. Through particular selection of the parameters CLT and KD, the rate of release of the biologically active agent from the matrix can be controlled.Type: GrantFiled: January 12, 2005Date of Patent: March 6, 2012Assignee: Clemson University Research FoundationInventors: Andrew T. Metters, Srinivas Chollangi
-
Patent number: 8118877Abstract: A membrane for implantation in soft tissue comprising a first domain that supports tissue ingrowth, disrupts contractile forces typically found in a foreign body response, encourages vascularity, and interferes with barrier cell layer formation, and a second domain that is resistant to cellular attachment, is impermeable to cells and cell processes, and allows the passage of analytes. The membrane allows for long-term analyte transport in vivo and is suitable for use as a biointerface for implantable analyte sensors, cell transplantation devices, drug delivery devices, and/or electrical signal delivering or measuring devices. The membrane architecture, including cavity size, depth, and interconnectivity, provide long-term robust functionality of the membrane in vivo.Type: GrantFiled: January 17, 2007Date of Patent: February 21, 2012Assignee: DexCom, Inc.Inventors: James H. Brauker, Mark A. Tapsak, Mark C. Shults
-
Patent number: 8119360Abstract: The present invention provides a method, a reagent and a kit for simple and sensitive determination of cholesterol in remnant-like particles without separation of components of a sample. A method for quantitatively determining remnant-like particle cholesterol in a sample, which comprises: in an aqueous medium containing the sample and in the presence of a combination of specific surfactants and a phospholipid-hydrolyzing enzyme, allowing remnant-like particle cholesterol in the sample to react with cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase (in the presence of oxidized coenzyme); and determining the formed hydrogen peroxide or reduced coenzyme.Type: GrantFiled: February 14, 2006Date of Patent: February 21, 2012Assignee: Kyowa Medex Co., Ltd.Inventors: Kazuhito Miyauchi, Mayumi Fujinaka
-
Patent number: 8034552Abstract: The present invention relates to virulent (lytic) Listeria monocytogenes phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce Listeria monocytogenes contamination. P100 can also be used in the present invention to identify Listeria monocytogenes bacteria present on (or within) foodstuffs, as well as those Listeria monocytogenes bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with Listeria monocytogenes. The phage and the endolysin of the present invention can also be used to treat animals infected with Listeria monocytogenes.Type: GrantFiled: August 28, 2008Date of Patent: October 11, 2011Assignee: E.B.I. Food Safety B.V.Inventors: Martin Loessner, Richard Carlton
-
Patent number: 7993906Abstract: The present invention provides a sensitive system for measuring the physiological response of an in-vitro cell culture to an environmental parameter. An electrical property of the cell culture is measured as a control signal, and a parameter of a stimulus is adjusted in real time to maintain the control signal at a specified value as the environment of the cell culture is altered, for example, pharmacologically. Artifact reduction and real-time control methods are two key aspects of preferred embodiments of the invention, and enable highly accurate determination of pulse parameters which elicit a desired response. Both aspects must be highly robust to the natural variations inherent in a biological system. This system is beneficial for studying the effects of environmental alterations because extremely small changes in the physiological response can be measured over time, revealing the magnitude and time-dependence of the impact of these alterations on the cell culture.Type: GrantFiled: May 24, 2005Date of Patent: August 9, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gregory T. A. Kovacs, R. Hollis Whittington